{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T13:41:15Z","timestamp":1776519675267,"version":"3.51.2"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["neurology.org"],"crossmark-restriction":true},"short-container-title":["Neurology"],"published-print":{"date-parts":[[2015,8,25]]},"DOI":"10.1212\/wnl.0000000000001870","type":"journal-article","created":{"date-parts":[[2015,7,25]],"date-time":"2015-07-25T03:45:20Z","timestamp":1437795920000},"page":"675-682","update-policy":"https:\/\/doi.org\/10.1212\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":133,"title":["Rapid progression of familial amyloidotic polyneuropathy"],"prefix":"10.1212","volume":"85","author":[{"given":"David","family":"Adams","sequence":"first","affiliation":[{"name":"From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unit\u00e9 1195, Le Kremlin-Bic\u00eatre, France; Hospital de Santo Ant\u00f3nio (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA."}]},{"given":"Teresa","family":"Coelho","sequence":"additional","affiliation":[{"name":"From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unit\u00e9 1195, Le Kremlin-Bic\u00eatre, France; Hospital de Santo Ant\u00f3nio (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA."}]},{"given":"Laura","family":"Obici","sequence":"additional","affiliation":[{"name":"From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unit\u00e9 1195, Le Kremlin-Bic\u00eatre, France; Hospital de Santo Ant\u00f3nio (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA."}]},{"given":"Giampaolo","family":"Merlini","sequence":"additional","affiliation":[{"name":"From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unit\u00e9 1195, Le Kremlin-Bic\u00eatre, France; Hospital de Santo Ant\u00f3nio (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA."}]},{"given":"Zoia","family":"Mincheva","sequence":"additional","affiliation":[{"name":"From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unit\u00e9 1195, Le Kremlin-Bic\u00eatre, France; Hospital de Santo Ant\u00f3nio (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA."}]},{"given":"Narupat","family":"Suanprasert","sequence":"additional","affiliation":[{"name":"From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unit\u00e9 1195, Le Kremlin-Bic\u00eatre, France; Hospital de Santo Ant\u00f3nio (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA."}]},{"given":"Brian R.","family":"Bettencourt","sequence":"additional","affiliation":[{"name":"From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unit\u00e9 1195, Le Kremlin-Bic\u00eatre, France; Hospital de Santo Ant\u00f3nio (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA."}]},{"given":"Jared A.","family":"Gollob","sequence":"additional","affiliation":[{"name":"From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unit\u00e9 1195, Le Kremlin-Bic\u00eatre, France; Hospital de Santo Ant\u00f3nio (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA."}]},{"given":"Pritesh J.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unit\u00e9 1195, Le Kremlin-Bic\u00eatre, France; Hospital de Santo Ant\u00f3nio (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA."}]},{"given":"William J.","family":"Litchy","sequence":"additional","affiliation":[{"name":"From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unit\u00e9 1195, Le Kremlin-Bic\u00eatre, France; Hospital de Santo Ant\u00f3nio (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA."}]},{"given":"Peter J.","family":"Dyck","sequence":"additional","affiliation":[{"name":"From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unit\u00e9 1195, Le Kremlin-Bic\u00eatre, France; Hospital de Santo Ant\u00f3nio (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA."}]}],"member":"276","reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.03.040"},{"key":"e_1_3_8_3_2","first-page":"88","volume-title":"Amyloid and Amyloidosis","author":"Coutinho P","year":"1980","unstructured":"Coutinho P, Martins da Silva A, Lopes Lima J, Resende Barbosa A. Forty years of experience with type I amyloid neuropathy: review of 483 cases. In: , Glenner GG, Pinho e Costa P, Falcao de Freitas A, editors. Amyloid and Amyloidosis. Amsterdam: Excerpta Medica; 1980:88\u201393."},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2007.05712.x"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111390"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.2174\/092986712800269236"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.3109\/13506120308998998"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2010.483114"},{"key":"e_1_3_8_9_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2000.3203"},{"key":"e_1_3_8_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10452"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.754348"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20644"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.32.920"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2012.685665"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182661eb1"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.283815"},{"key":"e_1_3_8_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.1.229"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410380323"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.06.041"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410110205"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0352"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2012.1481"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23982"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24243"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21661"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23765"},{"key":"e_1_3_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2005.08.016"},{"key":"e_1_3_8_28_2","unstructured":"Adams D Coelho T Obici L et al.. Neuropathy progression rate in patients with familial amyloidotic polyneuropathy. 2014. XIVth International Symposium on Amyloidosis (ISA); April 27\u2013May 1 2014; Indianapolis IN."},{"key":"e_1_3_8_29_2","unstructured":"European Medicines Agency. Assessment Report: Vyndaqel\u2014Tafamidis Meglumine. Report no. EMA\/729083\/2011 [online]. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002294\/human_med_001498.jsp&mid=WC0b01ac058001d124. Accessed December 17 2014."},{"key":"e_1_3_8_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-013-9512-x"},{"key":"e_1_3_8_31_2","unstructured":"Alnylam Pharmaceuticals. A phase 3 multicenter multinational randomized double-blind placebo-controlled study to evaluate the efficacy and safety of ALN-TTR02 in transthyretin (TTR)-mediated polyneuropathy (familial amyloidotic polyneuropathy\u2014FAP). Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01960348. Accessed December 17 2014."},{"key":"e_1_3_8_32_2","unstructured":"Isis Pharmaceuticals. A phase 2\/3 randomized double-blind placebo-controlled study to assess the efficacy and safety of ISIS 420915 in patients with familial amyloid polyneuropathy. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01737398. Accessed December 17 2014."},{"key":"e_1_3_8_33_2","unstructured":"Lane T Bangova A Fontana M et al.. TRANSCEND\u2014(transthyretin amyloidosis: neuropathy senility cardiomyopathy; evaluation natural history and diagnosis)\u2014a comprehensive observational study of transthyretin amyloidosis. 2014. XIVth International Symposium on Amyloidosis (ISA); April 27\u2013May 1 2014; Indianapolis IN."},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.754349"},{"key":"e_1_3_8_35_2","unstructured":"Rapezzi C Karayal ON Stewart M Mundayat R Suhr O. Markers of disease progression in transthyretin-related amyloidosis identified from a cross-sectional analysis of the THAOS registry. 2014. XIVth International Symposium on Amyloidosis (ISA); April 27\u2013May 1 2014; Indianapolis IN."},{"key":"e_1_3_8_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-301299"},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7124-7"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.0000000000001870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T13:20:57Z","timestamp":1711632057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.0000000000001870"}},"subtitle":["A multinational natural history study"],"short-title":[],"issued":{"date-parts":[[2015,8,25]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8,25]]}},"alternative-id":["10.1212\/WNL.0000000000001870"],"URL":"https:\/\/doi.org\/10.1212\/wnl.0000000000001870","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,25]]}}}